Clinical Trial Search

Primary: Annual Asthma Exacerbation Rate in Adult and Adolescent Patients With Uncontrolled Asthma for Patients With Baseline Eosinophils >=300/uL — 0.6; 0.66; 0.93 Events/year…

Primary: Number of Oocytes Retrieved — 3.3; 3.6 oocytes — p=0.054

Primary: Change From Baseline in Estimated Glomerular Filtration Rate - Month 12 — 6.2 mL/min/1.73m^2

Primary: Time to Intervention for Any Mood Episode (TIME) — NA; NA Days — p==0.438

Primary: The Percent of Patients With Clinically Significant Upper-GI Bleeding During the Treatment Evaluation Phase — 2.7; 4.6 % of participants — p=0.393

Primary: Non-inferiority of T2347 Compared With Xalacom® on Change in Mean IOP at 9.00 am (± 1 Hour) Between the Baseline (Day 0) and Day 84 in the Worse Eye — -0.51; -0.52 mm Hg

Primary: Percentage of Participants With Sustained Virological Response (SVR) (Groups A and B) — 48.8; 39.5 percentage of participants — p=0.510

Primary: Clinically Significant Atrial Fibrillation — 5; 6 Participants

Primary: Overall Survival — 88.7; 93.3 percentage of participants — p=0.0398

Primary: Percentage of Participants With Reduction in Muscle Pain Associated With Statin Use — 53; 65 % of participants with pain reduction

Primary: Observed Serum Trough Concentration (Ctrough) of Trastuzumab Prior to Surgery — 57.8; 78.7 μg/mL

Primary: Change From Baseline in HbA1c (Glycosylated Haemoglobin) — -1.90; -0.89 percentage of glycosylated haemoglobin — p=<0.0001

Primary: Percentage of Participants With Lesser Than or Equal to One Gram Per Deciliter Decrease in Average Hemoglobin From Baseline and Maintaining Average Hemoglobin Level…

Primary: Change From Baseline in HbA1c (Glycosylated Haemoglobin) — -0.43; -0.14 Percentage of glycosylated haemoglobin — p=0.427

Primary: Change From Baseline in HbA1c (Glycosylated Haemoglobin) — -1.81; -1.13 Percentage (%) — p=< 0.001